Bin Feng

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Pulmonary Artery

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Rutkowska-Klute, H Christian Eberl, Thilo Werner, Marco L Hennrich, Daniel C Sevin, Massimo Petretich, James P Reddington, Shirin Pocha, Stephan Gade, Amalia Martinez-Segura, Dmytro Dvornikov, Joel Karpiak, Gavain M A Sweetman, Christian Fufezan, Birgit Duempelfeld, Florian Braun, Christopher A Schofield, Hakan Keles, David Alvarado, Zhuo Wang, Keith H Jansson, Maria Fälth-Savitski, Edward Curry, Katja Remlinger, Euan A Stronach, Bin Feng, Geeta Sharma, Kevin Coleman, Paola Grandi, Marcus Bantscheff, Giovanna Bergamini
Synergistic effects of PARP inhibition and cholesterol biosynthesis pathway modulation. Cancer research communications (2024)
Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, Andrés Redondo, Michel Fabbro, Bobbie J Rimel, Jørn Herrstedt, Amit M Oza, Ulrich Canzler, Jonathan S Berek, Antonio Gonzáles Martin, Phillipe Follana, Rosemary Lord, Masoud Azodi, Kasey Estenson, Zebin Wang, Yong Li, Divya Gupta, Ursula A Matulonis, Bin Feng
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer research communications 2 (11) (2022)
Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, Andrés Redondo, Michel Fabbro, Bobbie J Rimel, Jørn Herrstedt, Amit M Oza, Ulrich Canzler, Jonathan S Berek, Antonio Gonzáles Martin, Phillipe Follana, Rosemary Lord, Masoud Azodi, Kasey Estenson, Zebin Wang, Yong Li, Divya Gupta, Ursula A Matulonis, Bin Feng
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer research communications 2 (11) (2022)